好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Minimally Invasive Surgery with Standard Care for Patients with Intracerebral Hemorrhage
Cerebrovascular Disease and Interventional Neurology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
4-009

This study aimed to evaluate whether minimally invasive surgery (MIS), in addition to standard care, improves clinical outcomes in patients with intracerebral hemorrhage (ICH), specifically with respect to 30-day mortality and 180-day functional disability, compared with medical management (MM) alone.
Randomized controlled trials (RCTs) investigating MIS for ICH have yielded inconclusive results regarding short-term survival and long-term functional outcomes. A recently published RCT in 2025 further reported no significant differences between MIS and MM for these endpoints, highlighting the need for a comprehensive synthesis of existing evidence.

A systematic search of PubMed and the Cochrane Library was performed to identify RCTs evaluating MIS compared with MM in patients with ICH. Eligible studies were required to report at least one of the following outcomes: (1) 30-day all-cause mortality, (2) symptomatic or asymptomatic rebleeding within 72 hours, and (3) favorable functional outcome at 180 days, defined as a modified Rankin Scale (mRS) score ≤3. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Statistical heterogeneity was assessed using the I² statistic.
Four RCTs comprising 1,138 patients were included (MIS: n = 613). MIS was associated with a lower 30-day mortality compared with MM (RR: 0.66; 95% CI: 0.48–0.92; p = 0.01). However, no difference was observed in mRS score ≤3 at 180 days between the two groups (RR: 1.12; 95% CI: 0.97–1.29; p = 0.13). Notably, MIS was associated with a higher risk of early rebleeding within 72 hours (RR: 3.47; 95% CI: 2.36–5.10; p < 0.00001). Across all outcomes, heterogeneity was minimal.
MIS appears to confer a survival advantage at 30 days without significant improvement in long-term functional outcomes compared with MM, though it carries a substantially higher risk of early rebleeding. Further high-quality RCTs are warranted to confirm these findings for MIS in ICH.
Authors/Disclosures
Duc Thien Ha Le
PRESENTER 		Ms. Le has nothing to disclose.
Nhan Nguyen, MD Mr. Nguyen has nothing to disclose.
Nghi B. Tran Miss Tran has nothing to disclose.
Tri Vinh Q. Ho Mr. Ho has nothing to disclose.
Vy N. Nguyen Miss Nguyen has nothing to disclose.
David Downes Mr. Downes has nothing to disclose.